OMER: Investor Sentiment and Bull/Bear Views
Omeros Corporation
Loading...
Loading...
Buzzberg insights
Attention & activity
- unique authors
- 1
- vs usual
- New
24h1
30d avg / day0
- unique authors
- 1
- vs usual
- +300%
7d1
4wk avg / week0.2
Author calls
What authors recommend
- Long
- —Authors: 0
- Short
- —Authors: 0
- Avoid
- —Authors: 0
- Long
- —Authors: 0
- Short
- —Authors: 0
- Avoid
- —Authors: 0
Author positions
What authors disclose
- Long
- —Authors: 0
- Short
- —Authors: 0
- Trimmed
- —Authors: 0
- Closed
- —Authors: 0
- Long
- —Authors: 0
- Short
- —Authors: 0
- Trimmed
- —Authors: 0
- Closed
- —Authors: 0
Feed & authors
- ideas
- 5
- Authors
- 4
- Sources
- 4
Call performance
Performance since each author’s call.
| Author | Direction | Return |
|---|---|---|
| u/liveninayellowsubJan 15 | Long | +14.2% |
Best calls over the past year · return since each call
Company facts
- Market cap
- $1.21B 2026-11-16
Financial results are not available yet.
Financial details
Market cap · polygon · 2026-11-16
Sentiment
Attention
1Newvs usual
unique authors
30d avg / day 0
Attention
1+300%vs usual
unique authors
4wk avg / week 0.2
Loading chart...
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
23:43
Sep 15
Sep 15
r/biotech_stocks
Reddit
OMER undervalued; Yartemla growth and Novo deal catalysts
The author argues Omeros is deeply undervalued, pointing to the CEO cutting 45% of debt and buying back 800,000 shares as signs of improving financial health. Yartemla sales are claimed to be expanding exponentially ($11M in Q1 to $33M in Q2), with NTAP and J-code approval beginning October 1st as a near-term reimbursement catalyst. A $2.1 billion deal with Novo Nordisk is said to include a near-term $100M payment, and Yartemla research into ARDs (a claimed 10x market) is expected to start by end of year. The author expects a 2x by end of year, with the main risk being reliance on these catalysts materializing as stated.
16:23
Jan 15
Jan 15
r/ValueInvesting
Reddit
FDA-approved drug launch catalyst to lift stock into $20s.
The author argues Omeros Corp (OMER) is undervalued after FDA approval of Yartemlea and a partnership with Novo Nordisk. Wainwright raised its price target to $40. The upcoming launch in the last week of January is expected to be a catalyst to lift the stock into at least the $20s.